PhRMA’s top lobbyist goes to a splashy startup
Rodger Currie, the head of lobbying for PhRMA is headed to Grail, the Silicon Valley startup working to create a blood test that would detect cancer in healthy people. (STAT scooped the news of his departure earlier this month.)
It’s an odd pairing, to be sure: Currie is known for his hard charging advocacy in Washington, and Grail has virtually no Washington presence. In fact, the company isn’t even registered in Congress’ lobbying database. Sounds like that's about to change.
“As GRAIL advances a novel paradigm for multi-cancer early detection, policymakers, payers, and other stakeholders must ensure that policies are in place to support the adoption of such groundbreaking technology,” Dr. Joshua Ofman, Grail’s chief of corporate strategy and external affairs, wrote in a press statement announcing the hire. “Rodger understands the challenge this represents, and we believe he is the ideal person to help us push our technology forward.”
For more on Grail, check out my colleague Matt Herper’s profile of the company.
It’s an odd pairing, to be sure: Currie is known for his hard charging advocacy in Washington, and Grail has virtually no Washington presence. In fact, the company isn’t even registered in Congress’ lobbying database. Sounds like that's about to change.
“As GRAIL advances a novel paradigm for multi-cancer early detection, policymakers, payers, and other stakeholders must ensure that policies are in place to support the adoption of such groundbreaking technology,” Dr. Joshua Ofman, Grail’s chief of corporate strategy and external affairs, wrote in a press statement announcing the hire. “Rodger understands the challenge this represents, and we believe he is the ideal person to help us push our technology forward.”
For more on Grail, check out my colleague Matt Herper’s profile of the company.
No hay comentarios:
Publicar un comentario